GlassScriptPhysician profile
Joseph B Helft
NPI 1659478477
$488,080.94
in general payments reported to CMS, 2019-2025
36 companies · $2,257 in 2025
The $2,257 reported for 2025 was more than what 85% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $143K · 2020: $42K · 2021: $62K · 2022: $122K · 2023: $39K · 2024: $78K · 2025: $2,257.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $111K · Food and Beverage: $7,170 · Travel and Lodging: $959 · Consulting Fee: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $110,756.25 |
| Food and Beverage | $7,169.55 |
| Travel and Lodging | $959.39 |
| Consulting Fee | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $186,917.44 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Janssen Pharmaceuticals, INC | $145,795.51 | 2019-2024 | Xarelto |
| Amgen INC. | $45,629.75 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45,226.66 | 2019-2025 | Jardiance |
| Pfizer INC. | $24,602.14 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $22,023.79 | 2019-2025 | Eliquis, Camzyos, Empliciti |
| Abbott Laboratories | $6,140.32 | 2019-2024 | Mitraclip, Jot Dx |
| Lilly USA, LLC | $4,651.95 | 2019-2025 | Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $1,379.71 | 2019-2025 | Farxiga, Wainua, Brilinta |
| Novartis Pharmaceuticals Corporation | $857.32 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $664.02 | 2021-2025 | Verquvo |
| Boston Scientific Corporation | $552.26 | 2019-2022 | |
| Vivaquant INC, Dba Rhythm Express | $500.00 | 2025 | Rhythm Express |
| Edwards Lifesciences Corporation | $437.68 | 2019-2025 | Sapien 3 Ultra Resilia |
| Sanofi-Aventis U.S. LLC | $421.87 | 2019-2023 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Helft listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.